Medication Overuse Headache: From Recognition and Withdrawal to Botox and CGRP-Based Management
Pain Spa | Dr M. Krishna | Specialist Interventional Pain Management
Medication Overuse Headache (MOH): A Comprehensive Clinical Guide
Understanding why frequent acute headache medication can worsen headache patterns — and how structured, personalised treatment can help break the cycle.
What Is Medication Overuse Headache?
Medication overuse headache (MOH) is a secondary headache disorder that develops when a person with a pre-existing primary headache disorder — most commonly migraine or tension-type headache — regularly overuses acute headache medication for more than three months. The result is a pattern of headache occurring on 15 or more days per month, often with a gradual shift from episodic attacks to a more persistent, chronic daily or near-daily headache pattern.
MOH is not simply “taking too many painkillers”. It reflects a complex change in pain processing. Frequent use of acute headache medicines can alter descending pain modulation, increase trigeminal system sensitivity, and reinforce a cycle in which short-term relief is followed by greater long-term headache vulnerability. This is why patients often feel trapped: they take medication because they have pain, but the repeated medication use may gradually make the headache system more excitable.
Diagnostic Criteria: ICHD-3
| Diagnostic Criterion | Explanation |
|---|---|
| Headache frequency | Headache occurs on ≥15 days per month. |
| Pre-existing headache disorder | Usually migraine or tension-type headache. |
| Medication overuse | Regular overuse of acute headache medication for more than three months. |
| Medication-specific threshold | ≥10 days/month for triptans, ergots, opioids or combination analgesics; ≥15 days/month for simple analgesics such as paracetamol or NSAIDs. |
| Exclusion | The headache is not better explained by another diagnosis. |
MOH affects approximately 1–2% of the adult population globally and is associated with substantial disability, reduced quality of life, psychological distress, increased healthcare use, and difficulty treating the underlying headache disorder.
Key Clinical Insight
Medication overuse headache reflects a change in how the brain processes pain, with reduced ability to suppress pain signals and increased sensitivity to triggers. This is why frequent short-term relief can paradoxically worsen long-term headache patterns.
Which Medications Can Cause MOH?
Different medications have different propensities to cause MOH. The risk depends on the medication class, frequency of use, duration of use, and the background headache disorder. Opioids and barbiturate-containing compounds carry the highest risk. Triptans and ergots have an intermediate risk. NSAIDs and paracetamol carry a lower risk, but they are still clearly recognised causes of MOH when used frequently enough.
Medication Classes and MOH Risk
Key Points on Risk Stratification
Highest-risk medications: Barbiturates and opioids are the most concerning. Butalbital-containing compounds may become problematic at very low frequencies and should generally be avoided in migraine. Opioids are also poor migraine treatments because they can promote central sensitisation, dependency, opioid-induced hyperalgesia, and difficult withdrawal.
Intermediate-risk medications: Triptans can cause MOH, but their risk is lower than opioids, barbiturates, and many combination analgesics. They remain effective acute migraine treatments when used within safe limits.
Lower-risk medications: NSAIDs and paracetamol have a higher threshold for MOH, but they are not risk-free. Their apparent safety can be misleading because patients often self-medicate with over-the-counter drugs without counting medication days.
Key clinical principle: Any acute headache medication can become problematic if the underlying headache disorder is not controlled and the patient begins using it regularly.
Does Paracetamol Cause MOH?
Yes — paracetamol is a recognised cause of medication overuse headache. Although it is widely available and often perceived as a “safe” first-line analgesic, frequent use can still contribute to the development and persistence of MOH.
The ICHD-3 threshold for paracetamol-related MOH is use on 15 or more days per month for more than three months. This places it in the lower-risk category compared to opioids or combination analgesics, but the risk remains clinically significant, particularly when patients use it regularly without monitoring frequency.
A common clinical scenario is the patient who takes paracetamol “as needed” for frequent headaches, often every other day or more. This pattern may seem reasonable to the patient but already approaches the threshold at which medication overuse can drive chronic headache patterns.
The key issue is not that paracetamol is inherently harmful, but that repeated exposure of the sensitised headache system to any acute medication can reinforce the cycle of headache and relief. For this reason, even simple analgesics should be used within clear limits, and frequent use should prompt consideration of preventive treatment.
Why Do Certain Medications Cause MOH but NSAIDs Less So?
The different risk between medication classes reflects how each drug affects central pain processing. MOH is not simply a toxic effect of medication. It is better understood as a state of altered pain modulation, where the nervous system becomes more responsive to headache triggers and less able to dampen pain signals.
Opioids and Barbiturates: Highest Risk
Opioids are strongly associated with MOH because they interfere with descending pain inhibition and can cause opioid-induced hyperalgesia. In practical terms, this means the nervous system becomes more sensitive to pain despite continued medication use. Repeated opioid exposure can suppress endogenous antinociceptive systems, alter brainstem pain modulation, and increase pronociceptive signalling through pathways involving CGRP and nitric oxide.
Barbiturate-containing products are also high-risk because of their central nervous system effects, dependency potential, and withdrawal risk. Abrupt cessation of butalbital-containing medication can be dangerous because of seizure risk, so tapering is required.
Triptans: Moderate Risk
Triptans can also cause MOH, but their risk is generally lower than opioids and barbiturates. With repeated exposure, triptans may alter serotonin receptor regulation, including downregulation of 5-HT1B/1D pathways and changes in excitatory cortical serotonin receptors. These changes may increase susceptibility to cortical spreading depression and migraine recurrence.
The paradox is that triptans are highly migraine-specific and effective when used appropriately, but they can still drive MOH when taken too frequently. This is why medication days, rather than medication strength, become central in prevention.
NSAIDs and Simple Analgesics: Lower Risk but Not Risk-Free
NSAIDs appear to carry a lower MOH risk partly because they act largely through peripheral anti-inflammatory mechanisms, particularly inhibition of prostaglandin synthesis. They may reduce meningeal inflammation and peripheral nociceptive input, thereby limiting central sensitisation when used occasionally.
However, at higher headache frequencies, NSAIDs lose this protective profile. In patients already experiencing headache on 10–14 days per month, frequent NSAID use may become a marker of worsening headache biology and may contribute to progression. The clinical message is that NSAIDs are safer than opioids or barbiturates, but they are not safe for near-daily use in headache patients.
Are NSAIDs or Any Other Medications Protective Against MOH?
NSAIDs have a nuanced relationship with MOH. They are not simply “protective” or “harmful”; their effect depends strongly on baseline headache frequency and pattern of use.
Naproxen and Possible Protective Effects
Long-acting NSAIDs such as naproxen may have a protective effect against transformation from episodic to chronic migraine when used at low frequency, particularly fewer than 10 days per month. Naproxen’s longer half-life and anti-inflammatory action may help reduce recurrent nociceptive input without causing the same rapid receptor adaptation seen with some migraine-specific agonists.
Naproxen is also commonly used as a bridging medication during withdrawal, often at 500 mg twice daily for a short period, provided the patient was not already overusing NSAIDs. The aim is not to substitute one overused drug for another, but to reduce the severity of withdrawal headache while preventive treatment and medication restriction are established.
NSAID Risk Depends on Baseline Headache Frequency
| Baseline Headache Frequency | NSAID Effect |
|---|---|
| 0–9 headache days/month | NSAIDs may be neutral or possibly protective. |
| 10–14 headache days/month | NSAIDs may be associated with progression toward chronic headache/MOH. |
| ≥15 headache days/month | NSAID use must be carefully reviewed because MOH may already be present. |
This distinction is crucial. A patient with occasional migraine taking naproxen several days per month is very different from a patient with near-daily headache taking ibuprofen most days of the week.
Preventive Treatments as Protective Strategies
The most reliable way to protect against MOH is not to find a “safe” acute medication for frequent use, but to reduce the number of headache days through effective prevention. Preventive treatments such as amitriptyline, topiramate, candesartan, beta-blockers, onabotulinumtoxinA, and CGRP monoclonal antibodies reduce MOH risk indirectly by reducing the need for acute medication.
CGRP-targeting therapies are particularly important because they can reduce migraine frequency and, in some studies, improve MOH even without mandatory formal withdrawal.
CGRP Antagonists, Gepants, and Ditans — Do They Cause MOH?
This is one of the most clinically important areas in modern migraine treatment. Gepants and ditans are both newer acute migraine treatments, but their MOH risk appears very different.
Comparison of Newer Migraine Treatments
| Drug Class | Examples | MOH Risk | Mechanism | Clinical Implication |
|---|---|---|---|---|
| Gepants | Ubrogepant, rimegepant, zavegepant, atogepant | No evidence of MOH | CGRP receptor antagonism | Useful in patients at risk of MOH. |
| Ditans | Lasmiditan | Likely possible MOH risk | 5-HT1F receptor agonism | Use frequency caution similar to triptans. |
| CGRP monoclonal antibodies | Erenumab, fremanezumab, galcanezumab, eptinezumab | No MOH risk | Preventive CGRP pathway blockade | Can reduce headache frequency and acute medication need. |
Why Gepants Appear Different
The key distinction is antagonist versus agonist. Traditional MOH-associated medications such as triptans, opioids, and ditans activate receptor systems. Repeated activation can trigger compensatory receptor changes, central sensitisation, and latent sensitisation.
Gepants, by contrast, are receptor antagonists. They block CGRP signalling without repeatedly activating the receptor. This appears to avoid the compensatory neuroplastic changes associated with MOH. Long-term clinical data for rimegepant and ubrogepant, as well as preventive use of atogepant and every-other-day rimegepant, have not shown a clear MOH signal.
Ditans: More Caution Required
Lasmiditan is a 5-HT1F agonist. Preclinical evidence suggests it can produce latent sensitisation similar to triptans. Clinical MOH data are less extensive than for older medications, but because lasmiditan is an agonist acting on serotonergic pathways, frequent use should be approached cautiously.
Practical Message
Gepants are attractive for patients with high-frequency migraine, patients at risk of MOH, and patients who cannot use triptans. They may be especially useful where acute treatment is needed but further medication overuse risk must be avoided.
Do Prophylactic Headache Medications Cause MOH?
No. Preventive headache medications do not cause medication overuse headache.
This is a very important distinction for patients. MOH is caused by frequent use of acute or symptomatic headache medications, not by preventive medications taken regularly to reduce headache frequency.
Preventive medications such as amitriptyline, topiramate, propranolol, candesartan, sodium valproate, onabotulinumtoxinA, and CGRP monoclonal antibodies work by reducing migraine susceptibility. They do not repeatedly suppress individual headache attacks in the same way that acute medications do, and they do not create the same cycle of short-term relief followed by long-term sensitisation.
Preventive Medications Are Used to Treat MOH
| Preventive Treatment | Role in MOH |
|---|---|
| Amitriptyline | Useful where insomnia, depression, anxiety, or tension-type features coexist. |
| Topiramate | Evidence supports benefit in chronic migraine with medication overuse. |
| Beta-blockers | Useful in selected patients; may help autonomic withdrawal symptoms. |
| Candesartan | Well tolerated option for migraine prevention. |
| OnabotulinumtoxinA | Useful in chronic migraine, including patients with medication overuse. |
| CGRP monoclonal antibodies | Increasing evidence for inducing MOH remission even without mandatory withdrawal. |
Practical message: Preventive therapy should be framed as part of the solution, not as another medication burden.
How Is MOH Diagnosed?
MOH is a clinical diagnosis. There is no blood test, scan, or biomarker that confirms it. The diagnosis is made from the history: headache frequency, medication use frequency, duration of overuse, and the underlying headache disorder.
ICHD-3 Diagnostic Framework
| Criterion | Requirement |
|---|---|
| Headache frequency | ≥15 days per month. |
| Background headache | Pre-existing primary headache disorder. |
| Medication use | Regular overuse for more than three months. |
| Medication threshold | Depends on drug class. |
| Exclusion | Not better accounted for by another headache diagnosis. |
Medication-Specific Diagnostic Thresholds
| Medication Class | MOH Threshold |
|---|---|
| Simple analgesics / NSAIDs / paracetamol | ≥15 days/month |
| Triptans | ≥10 days/month |
| Ergots | ≥10 days/month |
| Opioids | ≥10 days/month |
| Combination analgesics | ≥10 days/month |
| Multiple acute medication classes | ≥10 days/month combined |
Key Diagnostic Points
Count medication days, not tablets.
If a patient takes sumatriptan three times in one day, that counts as one medication day.
Ask specifically about over-the-counter medication.
Patients often forget paracetamol, ibuprofen, aspirin, caffeine-containing compounds, and combination cold remedies.
Ask about medication used for non-headache pain.
Opioids, NSAIDs, and codeine-containing medication used for back pain, pelvic pain, arthritis, or dental pain can still contribute to MOH.
Dual diagnosis is allowed.
A patient can have chronic migraine and MOH at the same time. MOH does not replace the underlying diagnosis.
Imaging is not routinely required.
Neuroimaging is reserved for red flags, abnormal neurological findings, new headache phenotype, cancer/infection concern, thunderclap onset, or other features suggesting secondary headache.
Safe Use Thresholds to Prevent MOH
The safest strategy is to keep acute medication use below the diagnostic threshold and below the level at which headache chronification becomes more likely. The practical clinical rule is: acute headache medication should generally be limited to no more than two days per week.
Safe Use Threshold Table
| Medication Class | ICHD-3 MOH Threshold | Practical Safe Limit |
|---|---|---|
| Simple analgesics / NSAIDs / paracetamol | ≥15 days/month | Ideally ≤10 days/month |
| Triptans | ≥10 days/month | Ideally ≤8 days/month |
| Combination analgesics | ≥10 days/month | Ideally ≤8 days/month |
| Opioids | ≥10 days/month | Avoid for migraine |
| Barbiturate-containing compounds | ≥10 days/month, but risk may occur earlier | Avoid |
| Gepants | No established MOH threshold | No clear MOH signal |
Practical Patient Message
“It is not only the strength of the medication that matters; it is the number of days your brain is exposed to acute medication.”
If a patient regularly needs acute medication more than two days per week, the priority should be to improve prevention rather than simply rotate acute medicines.
Treatment of MOH
Treatment of MOH requires a structured approach. The most successful strategies combine education, reduction or withdrawal of the overused medication, preventive treatment, bridging support, behavioural strategies, and follow-up. Simply telling patients to “stop painkillers” is rarely enough and can feel punitive. The patient needs to understand the biology, the plan, the expected withdrawal phase, and the long-term benefit.
Step 1: Patient Education
Education is not a soft add-on; it is the foundation of treatment. Patients need to understand that MOH is not their fault and not a sign of weakness or addiction in most cases. It is a predictable neurobiological response to repeated acute medication exposure in a sensitised headache system.
| Education Point | Why It Matters |
|---|---|
| MOH mechanism | Helps patients understand why short-term relief can worsen long-term headache. |
| Medication-day counting | Makes risk visible and measurable. |
| Withdrawal symptoms | Reduces anxiety when headache initially worsens. |
| Preventive treatment | Reframes treatment as adding control rather than removing relief. |
| Relapse prevention | Prevents return to overuse after initial success. |
Step 2: Withdrawal or Restriction of the Overused Medication
Withdrawal remains a cornerstone of MOH treatment, but the approach depends on the drug class.
| Medication Class | Preferred Withdrawal Strategy | Expected Withdrawal Duration | Key Considerations |
|---|---|---|---|
| Triptans | Abrupt withdrawal often preferred | ~4 days | Shorter withdrawal period and generally favourable prognosis. |
| NSAIDs / simple analgesics | Abrupt withdrawal often preferred | ~9–10 days | Longer rebound headache but usually uncomplicated. |
| Ergotamines | Abrupt withdrawal | ~6–7 days | Requires monitoring for recurrence. |
| Combination analgesics | Often abrupt, unless sedative/opioid component | Variable | Caffeine withdrawal may contribute. |
| Opioids | Gradual taper | Variable | Risk of physiological withdrawal; may need specialist input. |
| Barbiturates / benzodiazepines | Gradual taper | Variable | Abrupt withdrawal may cause seizures; inpatient care may be required. |
Withdrawal symptoms may include worsening headache, nausea, vomiting, restlessness, anxiety, tachycardia, sleep disturbance, and general malaise. Patients should be warned that the first week can be difficult, particularly with triptans and ergots, and sometimes longer with analgesics or opioids.
Step 3: Start Preventive Treatment
Preventive treatment should usually be started at the time of withdrawal or shortly before. This gives patients a sense that something positive is being introduced rather than simply removing their rescue medication.
Preventive Medication Options in MOH
| Preventive Agent | Typical Dose Range | Advantages | Cautions |
|---|---|---|---|
| Topiramate | 50–200 mg/day | Evidence in chronic migraine/MOH; useful where weight loss is acceptable. | Cognitive side effects, paraesthesia, teratogenicity. |
| Amitriptyline | 10–75 mg at night | Useful with insomnia, anxiety, depression, tension-type features. | Sedation, weight gain, anticholinergic effects. |
| Candesartan | 16–32 mg/day | Often well tolerated. | Hypotension, avoid in pregnancy. |
| Beta-blockers | Agent-dependent | Useful with hypertension or tremor/anxiety. | Avoid in asthma, bradycardia. |
| OnabotulinumtoxinA | 155–195 units every 12 weeks | Useful in chronic migraine. | Requires chronic migraine diagnosis; response may take cycles. |
| CGRP monoclonal antibodies | Per product licence | Strong emerging evidence in MOH; may work without withdrawal. | Cost/access; pregnancy considerations. |
Step 4: Bridging Therapy
Bridging therapy can help patients get through the withdrawal phase. It should not become another form of overuse.
| Bridging Option | Role |
|---|---|
| Naproxen short course | Useful if NSAIDs were not the overused medication. |
| Antiemetics | Useful for nausea/vomiting and migraine-associated symptoms. |
| Greater occipital nerve block | Can reduce withdrawal headache and reduce rescue medication need. |
| Neuromodulation devices | Non-drug support during withdrawal. |
| Steroids | Evidence mixed; not routinely reliable. |
Step 5: Behavioural and Psychological Support
Behavioural support is essential, especially for patients with anxiety, depression, trauma history, sleep disturbance, or fear of untreated pain. CBT, relaxation training, biofeedback, sleep regularisation, pacing, exercise, and motivational interviewing can help sustain withdrawal and prevent relapse.
Treatment Flowchart
Counselling Patients Approaching MOH Thresholds
This is one of the most important clinical conversations because it can prevent MOH before it becomes established. The tone matters. Patients are usually taking frequent medication because they are frightened of pain, disabled by headache, or trying to function at work and home. The conversation should avoid blame.
When to Start the Conversation
| Clinical Scenario | Recommended Action |
|---|---|
| ≥6 headache days/month | Offer preventive therapy. |
| ≥4 headache days/month with impairment | Offer preventive therapy. |
| ≥3 headache days/month with severe impairment | Consider/offer preventive therapy. |
| Acute medication use approaching ≥2 days/week | Discuss MOH risk and prevention. |
| Escalating medication use despite treatment | Review diagnosis and prevention strategy. |
Key Counselling Box
1. Reframe the problem:
“Your brain is becoming more sensitive, not tougher. The tablets help in the short term, but frequent use can make the headache system more reactive.”
2. Use a headache diary:
Patients often underestimate medication days. A diary turns an invisible pattern into something measurable.
3. Frame prevention as adding control:
The aim is not to take away rescue medication. The aim is to reduce the number of days the patient needs it.
4. Set realistic expectations:
Preventive treatment often takes 4–8 weeks to show benefit. The goal is usually a meaningful reduction in headache days, not complete elimination.
5. Teach the two-day rule:
Acute medication should generally be limited to no more than two days per week.
6. Address fear:
Patients need reassurance that they will not be abandoned without pain relief during withdrawal.
Evidence Comparing Withdrawal Strategies
Withdrawal strategy has evolved. Historically, complete withdrawal was considered mandatory. More recent evidence suggests that some patients improve with preventive therapy even without strict withdrawal, particularly when modern migraine-specific preventives are used. However, withdrawal remains highly effective and should still be considered a central strategy in many patients.
Complete Withdrawal vs Restricted Intake
A Danish randomised trial compared complete withdrawal of acute medication with restricted intake to two days per week. Complete withdrawal produced a larger reduction in headache days and a higher rate of reversion to episodic headache. Interestingly, patients often found complete withdrawal more feasible than restricted use because the rule was clearer: “none” can be easier to follow than “a little, but not too much”.
| Strategy | Advantages | Limitations |
|---|---|---|
| Complete withdrawal | Clear rule, strong evidence, faster reset. | Difficult early withdrawal period. |
| Restricted intake | Less intimidating, may suit selected patients. | Ambiguity can lead to drift back into overuse. |
| Preventive therapy without withdrawal | Useful when withdrawal is not feasible. | May not reduce medication dependence enough. |
| Withdrawal + prevention | Often best overall strategy. | Requires support and monitoring. |
Withdrawal Plus Preventive Therapy
Evidence suggests that combining withdrawal with preventive medication is often more effective than either strategy alone. This makes clinical sense: withdrawal addresses the medication-driven component, while prevention addresses the underlying migraine biology.
The MOST Trial and the Modern Shift
The Medication Overuse Treatment Strategy trial challenged the idea that every patient must formally withdraw before preventive treatment begins. Starting preventive medication without switching the overused medication was non-inferior for some headache outcomes. However, restricting or switching medication still reduced symptomatic medication days, which remains important for relapse prevention.
Practical Interpretation
For most patients overusing triptans, simple analgesics, or NSAIDs, outpatient withdrawal or restriction with immediate preventive treatment is reasonable. For opioids, barbiturates, benzodiazepines, multiple medication classes, severe psychiatric comorbidity, or previous failed withdrawal, a more supervised or inpatient approach may be needed.
Relapse Rates and Long-Term Relapse Prevention
MOH relapse is common, particularly in the first year after successful withdrawal. This is why long-term follow-up is not optional. The goal is not only to stop overuse but to prevent the patient drifting back into the same pattern when headaches flare again.
Relapse Rates Over Time
| Time Point | Approximate Relapse Rate | Clinical Meaning |
|---|---|---|
| 6 months | Around 11% with combined treatment | Best outcomes when withdrawal and prevention are combined. |
| 1 year | 25–38% | Highest risk period. |
| 4 years | 42–44% | Only modest increase beyond year 1. |
| 5 years | Around 40% | Risk plateaus in patients who remain stable after year 1. |
Predictors of Relapse
Patients are more likely to relapse if they have tension-type headache as the dominant phenotype, overuse combination analgesics, resume the original causative medication, have untreated depression or anxiety, or have very high baseline headache frequency. Combination analgesic overuse is particularly problematic because it often includes caffeine, codeine, sedatives, or multiple active ingredients that reinforce repeated use.
Relapse Prevention Strategy
Relapse prevention should be written down and agreed with the patient. It should include strict acute medication limits, ongoing preventive therapy for at least 6–12 months, headache diary monitoring, regular follow-up, behavioural support, and early intervention if medication days begin to creep upward.
For patients at high relapse risk, gepants may be considered as acute treatment because they have not shown the same MOH signal as traditional acute treatments. CGRP monoclonal antibodies may also be considered where migraine remains frequent despite oral prevention.
Managing Refractory MOH — Inpatient Detoxification and Multidisciplinary Approaches
Refractory MOH refers to patients who do not improve with standard education, outpatient withdrawal, medication restriction, and preventive therapy. These patients often have more complex biology and psychosocial drivers, including psychiatric comorbidity, chronic pain elsewhere, opioid or barbiturate use, sleep disturbance, trauma, or repeated failed withdrawal attempts.
Indications for Inpatient or Specialist Detoxification
| Indication | Why It Matters |
|---|---|
| Failed outpatient withdrawal | Suggests need for structured support. |
| Opioid overuse | Risk of significant withdrawal and dependency. |
| Barbiturate/benzodiazepine overuse | Seizure risk with abrupt withdrawal. |
| Multiple medication classes | More complex withdrawal and relapse risk. |
| Status migrainosus/intractable vomiting | May need IV treatment. |
| Severe psychiatric comorbidity | Requires integrated psychological/psychiatric care. |
| Significant medical comorbidity | Needs monitoring. |
Inpatient IV DHE Protocols
IV dihydroergotamine (DHE), often using a Raskin-style protocol, remains one of the established inpatient strategies for refractory chronic headache and MOH. It is typically given with antiemetic premedication such as metoclopramide. The aim is to break the cycle of persistent migraine and medication overuse under monitored conditions.
DHE is not suitable for everyone and is contraindicated in pregnancy, significant vascular disease, uncontrolled hypertension, and some other medical situations. In selected refractory patients, however, inpatient DHE can be very effective.
Adjunctive IV Options
| Treatment | Role |
|---|---|
| IV magnesium | Useful in selected migraine/status migrainosus patients. |
| IV metoclopramide/prochlorperazine | Antiemetic and anti-migraine effect. |
| IV steroids | May help status migrainosus; evidence mixed. |
| IV ketorolac | Only if NSAIDs are not the overused class. |
| IV lidocaine/ketamine | Specialist refractory headache use only. |
| IV valproate | Selected intractable migraine cases; avoid in pregnancy. |
Opioids should generally be avoided in inpatient headache management because they worsen long-term headache outcomes, increase dependency risk, and may perpetuate MOH.
Multidisciplinary Headache Programmes
A multidisciplinary approach is often more effective than medication adjustment alone. Effective programmes combine:
| Component | Role |
|---|---|
| Headache specialist | Confirms diagnosis and supervises medication plan. |
| Psychology/psychiatry | CBT, anxiety/depression treatment, substance-use support. |
| Physiotherapy | Cervical, postural, and exercise-based rehabilitation. |
| Behavioural medicine | Biofeedback, relaxation, sleep regulation. |
| Specialist nursing | Diary support, education, relapse monitoring. |
This approach is particularly relevant for patients who have failed repeated medication-only strategies.
Role of Injections and Pain Interventions in MOH Management
Injections and pain interventions are not primary cures for MOH, but they can play an important bridging and adjunctive role. Their value is greatest during withdrawal, when patients are vulnerable to rebound headache and may be tempted to restart the overused medication.
The most important principle is that interventions should support the overall MOH plan. They should reduce headache burden, reduce reliance on acute medication, and improve the patient’s ability to complete withdrawal and engage with preventive therapy.
Main Interventional Options
| Intervention | Role in MOH |
|---|---|
| Greater occipital nerve block | Best-supported bridge during withdrawal. |
| Supraorbital / supratrochlear nerve blocks | Useful in frontal-predominant headache. |
| Auriculotemporal nerve block | Useful in temporal-predominant headache. |
| Trigger point injections | Adjunct when myofascial trigger points contribute. |
| OnabotulinumtoxinA | Preventive treatment for chronic migraine with/without MOH. |
| Occipital nerve stimulation | Reserved for highly refractory chronic migraine; MOH should be treated first. |
Greater occipital nerve block is the most relevant procedure in MOH because it can provide non-opioid, non-tablet relief during the most difficult withdrawal phase. This fits well with Pain Spa’s precision image-guided approach, particularly where headache pain has occipital, cervicogenic, or trigeminocervical features.
Greater Occipital Nerve Block: Protocol and Optimal Injection Frequency
Greater occipital nerve block (GONB) can be used as a transitional treatment during MOH withdrawal. It may reduce headache severity, improve tolerability of withdrawal, and reduce the urge to return to overused acute medication.
Per your instruction, I am not expanding the detailed injection technique here.
Clinical Role of GONB in MOH
| Use Case | Rationale |
|---|---|
| Withdrawal bridge | Reduces rebound headache without adding oral medication burden. |
| Occipital-predominant headache | Targets occipital/cervical contribution. |
| Migraine with neck/occipital pain | Modulates trigeminocervical complex. |
| High medication anxiety | Provides a non-tablet rescue strategy. |
| Pregnancy | Can be particularly useful when medication options are restricted. |
Suggested Frequency Framework
Steroid is not always required. In migraine and MOH, local anaesthetic alone may be sufficient, and evidence does not clearly show added benefit from corticosteroid in this setting.
Combining GONB with Other Peripheral Nerve Blocks
GONB can help frontal and temporal headache because of convergence within the trigeminocervical complex. Cervical afferents and trigeminal afferents meet in shared brainstem/cervical pathways, which explains why blocking an occipital nerve can sometimes improve pain felt in the forehead, temple, or around the eye.
However, some patients have dominant frontal, temporal, or diffuse scalp pain. In these cases, combining GONB with other peripheral nerve blocks may provide broader coverage.
Peripheral Nerve Block Selection Table
| Nerve Block | Sensory Territory | Best Clinical Use |
|---|---|---|
| Greater occipital nerve | Posterior scalp to vertex | Occipital, posterior, neck-associated migraine. |
| Lesser occipital nerve | Lateral occipital scalp and posterior ear | Lateral occipital pain. |
| Supraorbital nerve | Forehead, anterior scalp, upper eyelid | Frontal or supraorbital headache. |
| Supratrochlear nerve | Medial forehead and bridge of nose | Medial frontal pain. |
| Auriculotemporal nerve | Temporal scalp, TMJ region, anterior ear | Temporal-predominant migraine/headache. |
Practical Approach
| Pain Distribution | Suggested Block Strategy |
|---|---|
| Occipital-predominant | Bilateral GONB ± lesser occipital nerve block. |
| Frontal-predominant | GONB + supraorbital/supratrochlear blocks. |
| Temporal-predominant | GONB + auriculotemporal block. |
| Holocranial/diffuse | Consider multiple cranial nerve blocks. |
| Failed GONB alone | Broaden coverage based on pain map. |
This is an area where careful clinical mapping matters. The procedure should be tailored to the patient’s dominant pain distribution rather than applied as a generic package.
Role of TENS and the Cefaly Device in MOH
TENS-based neuromodulation and the Cefaly device have a limited but useful role in MOH. They should be presented as adjuncts rather than replacements for withdrawal and preventive therapy.
Cefaly is an external trigeminal nerve stimulation device that stimulates the supraorbital and supratrochlear nerves. It can be used preventively or acutely, depending on the treatment mode. Its main attraction in MOH is that it provides a non-drug option during withdrawal, when patients are trying to reduce acute medication use.
Practical Use in MOH
| Scenario | Potential Role |
|---|---|
| During withdrawal | Non-drug bridge for rebound headache. |
| High medication anxiety | Gives patient a rescue option without tablets. |
| Frequent migraine | Adjunct to preventive strategy. |
| Pregnancy or medication restriction | Useful where drug options are limited. |
| Patient preference for non-drug therapy | Can improve engagement. |
The evidence specifically in MOH remains limited, but the risk profile is favourable. It is best framed as part of a broader plan, not as a stand-alone treatment.
Stepwise Management Protocol for MOH
This is the practical clinical pathway.
Stepwise MOH Management Table
| Step | Intervention | Purpose | Timing |
|---|---|---|---|
| 1 | Confirm diagnosis | Establish headache days, medication days, and underlying headache type | First consultation |
| 2 | Educate patient | Explain MOH mechanism and treatment plan | First consultation |
| 3 | Identify overused medication | Determines abrupt withdrawal vs taper | First consultation |
| 4 | Start preventive therapy | Reduce headache frequency and acute medication need | At or before withdrawal |
| 5 | Withdraw/restrict acute medication | Break medication-driven sensitisation | Weeks 1–4 |
| 6 | Add bridging therapy | Support withdrawal and reduce relapse to overuse | Weeks 1–4 |
| 7 | Reassess | Measure headache days and medication days | 6–12 weeks |
| 8 | Escalate if needed | CGRP mAbs, Botox, inpatient pathway, multidisciplinary care | 3–6 months |
| 9 | Prevent relapse | Diary, medication limits, continued prevention | Ongoing |
Narrative Protocol
The first consultation should focus on diagnosis, explanation, and building trust. The patient should leave understanding that MOH is reversible but requires a structured plan. A medication diary should be started immediately if one is not already available.
For triptans, NSAIDs, and simple analgesics, abrupt withdrawal or strict restriction can often be attempted as an outpatient. For opioids, barbiturates, benzodiazepines, or multiple medication overuse, tapering and specialist support are safer.
Preventive therapy should not be delayed unnecessarily. If the patient has frequent migraine, starting prevention early gives them a realistic chance of reducing acute medication reliance. Bridging therapy such as GONB, antiemetics, short NSAID course if appropriate, or neuromodulation can support the most difficult phase.
At 2–3 months, the clinician should reassess headache frequency, acute medication days, disability, side effects, and adherence. If the patient has improved, prevention should continue for at least 6–12 months. If response is partial, preventive treatment should be optimised or escalated. If there is no response, reconsider the diagnosis, check for ongoing overuse, address comorbidities, and consider CGRP therapy, Botox, or specialist headache referral.
Management of MOH in Pregnancy
MOH in pregnancy is particularly challenging because many effective migraine preventives and withdrawal treatments are contraindicated or restricted. At the same time, repeated use of safe acute medications such as paracetamol can still perpetuate MOH if used too frequently.
The management principle in pregnancy is to prioritise education, medication audit, non-pharmacological strategies, pregnancy-compatible preventives where needed, and carefully selected bridging treatments.
Step 1: Medication Audit and Risk Assessment
The first step is to identify exactly what is being overused. Particular caution is needed with opioids, butalbital-containing products, ergotamines, and frequent NSAID use. Ergotamines are contraindicated. NSAIDs are generally avoided in the third trimester and used only cautiously, usually in the second trimester if required.
Paracetamol may be used in pregnancy, but frequent use can still contribute to MOH. Therefore, the target should still be to keep acute medication use as low and infrequent as possible.
Step 2: Non-Pharmacological First-Line Strategy
| Strategy | Role |
|---|---|
| Headache diary | Tracks headache days and medication days |
| Sleep regularity | Reduces migraine instability |
| Hydration and regular meals | Reduces avoidable triggers |
| Physiotherapy | Addresses cervical/myofascial contribution |
| Relaxation / CBT / biofeedback | Helps coping and relapse prevention |
| GONB with local anaesthetic | Useful non-systemic bridge in selected cases |
| Cefaly / neuromodulation | Non-drug adjunct |
Pregnancy: Key Differences from Non-Pregnant MOH
| Management Area | Non-Pregnant Patient | Pregnant Patient |
|---|---|---|
| First-line prevention | Topiramate, amitriptyline, candesartan, CGRP mAbs, Botox | More restricted; specialist obstetric input needed |
| CGRP therapies | Increasing role | Generally avoided |
| DHE | Inpatient refractory option | Contraindicated |
| NSAIDs | Possible bridge | Limited use, usually second trimester only |
| Nerve blocks | Adjunctive | Often more central |
| Behavioural therapy | Important adjunct | First-line foundation |
Step 3: Refractory MOH in Pregnancy
If outpatient management fails, specialist multidisciplinary care is needed. Options may include inpatient hydration, antiemetics compatible with pregnancy, IV magnesium in selected cases, serial nerve blocks, behavioural therapy, and obstetric monitoring.
OnabotulinumtoxinA may sometimes be discussed in severe chronic migraine during pregnancy because systemic absorption is low, but this remains a specialist decision and should be individualised.
Role of Botox (OnabotulinumtoxinA) in the Management of MOH
OnabotulinumtoxinA is an established preventive treatment for chronic migraine and has been studied in patients with medication overuse. It is not a detoxification treatment in itself, but it can reduce headache frequency, reduce migraine burden, and reduce reliance on acute medication.
The standard chronic migraine approach is based on the PREEMPT protocol, using 155–195 units every 12 weeks. Benefit may not be clear after the first treatment cycle, so patients usually require at least two to three cycles before response is judged.
| Situation | Role of Botox |
|---|---|
| Chronic migraine with MOH | May reduce headache frequency and acute medication use |
| Failed oral preventives | Stronger indication |
| Unable to tolerate oral medication | Useful non-oral preventive option |
| Withdrawal successful but chronic migraine persists | Appropriate next-step preventive |
| Ongoing severe MOH | Consider, but withdrawal/restriction still important |
Some evidence suggests Botox can help patients with chronic migraine whether or not medication overuse is present. However, other studies suggest that when withdrawal is successfully performed, Botox may not add much beyond withdrawal alone. This is why practice varies between a strict withdrawal-first model and a more pragmatic model where Botox is started in patients who cannot successfully withdraw or remain highly disabled.
Why Does NICE Exclude Patients with MOH from Botox Treatment for Chronic Migraine?
NICE requires medication overuse to be appropriately managed before Botox is used for chronic migraine. The logic is clear, even though it is debated.
1. Diagnostic Clarity
If a patient has chronic migraine and MOH, it may be unclear whether the patient has true refractory chronic migraine or whether the chronic pattern is being driven by medication overuse. If withdrawal alone converts the headache pattern back to episodic migraine, Botox may not be necessary.
2. Cost-Effectiveness
Botox is more expensive than medication withdrawal. From a NICE perspective, if a low-cost withdrawal intervention can improve a substantial proportion of patients, it should be attempted first.
3. Treatment Response Assessment
NICE requires Botox to be stopped if response is inadequate after treatment cycles. If medication overuse continues, it becomes difficult to know whether lack of improvement is due to Botox failure, ongoing MOH, poor withdrawal, or natural fluctuation.
Balanced Clinical View
The NICE position is rational from a pathway and cost-effectiveness standpoint. However, it can create a bottleneck for patients who cannot successfully withdraw despite repeated attempts. Modern evidence with Botox and CGRP monoclonal antibodies increasingly supports a more flexible approach in selected patients, especially those with severe chronic migraine, disability, and failed withdrawal attempts.
Stepwise Approach to Using Botox in Patients with MOH and Migraine
Botox Pathway Table
Clinical Explanation
Before Botox, the clinician should document headache days, migraine days, acute medication days, disability scores, previous preventive trials, and the specific medication being overused. This baseline is essential because Botox response must be judged against meaningful outcomes, not general impressions.
Where possible, medication withdrawal or restriction should be attempted first, especially for simple analgesic, NSAID, or triptan overuse. In opioid or barbiturate overuse, tapering or specialist detoxification may be required.
If the patient remains in chronic migraine after withdrawal, Botox becomes a logical next step. If the patient cannot withdraw despite repeated attempts, Botox may still be clinically reasonable, especially where disability is high and oral preventives have failed or are poorly tolerated.
Botox should not be judged too early. Many patients need two to three cycles, and some apparent non-responders at two cycles may respond later. Treatment should be integrated with medication limits, diary monitoring, and relapse prevention.
Injection Technique Modifications and “Follow the Pain” Strategies
The PREEMPT protocol for chronic migraine uses a fixed-site, fixed-dose framework with optional additional dosing in pain-dominant regions. This is where the “follow the pain” concept becomes clinically relevant.
The aim is not to abandon the PREEMPT protocol, but to personalise the optional injection sites based on the patient’s dominant pain distribution. Many chronic migraine patients have clear patterns: frontal, temporal, occipital, neck-dominant, jaw/temporalis-associated, or holocranial. Mapping this pattern improves the logic of treatment.
Follow-the-Pain Strategy
Important Anatomical Considerations
The frontalis must be treated carefully because excessive weakening can cause brow ptosis. Corrugator and procerus injections require attention to avoid diffusion-related eyelid ptosis. Temporalis injections should reflect tenderness and pain distribution. Occipital and trapezius dosing should consider the patient’s posterior headache and neck muscle tenderness.
Clinical Value
“Follow the pain” is particularly useful when the patient’s migraine phenotype is not evenly distributed. It allows the treatment to remain evidence-based while acknowledging that chronic migraine is clinically heterogeneous. The best results often come from combining protocol discipline with anatomical judgement.
The Follow-The-Sutures Injection Paradigm
The Follow-The-Sutures paradigm is an emerging concept that proposes targeting cranial suture lines rather than only muscles. The theory is that meningeal nociceptive afferents may communicate with extracranial tissues through cranial sutures and emissary pathways, meaning suture regions could act as relevant pain interfaces in some headache patients.
This remains an evolving paradigm and should not be presented as replacing PREEMPT. It is better framed as a developing anatomical and mechanistic idea that may help explain why some patients respond to injections in regions not fully explained by muscle anatomy alone.
PREEMPT vs Follow-The-Sutures
Practical Interpretation
For Pain Spa-style patient education, this section should be presented cautiously. It is interesting and anatomically plausible, but not yet the standard of care. The safest wording is that PREEMPT remains the established evidence-based approach, while “follow-the-pain” and suture-informed strategies may help experienced clinicians individualise treatment in selected patients.
Pain Spa Expert Perspective
Medication overuse headache is one of the most important reversible causes of chronic daily headache. The key is not simply to stop medication, but to understand why the patient reached that point. In most cases, medication overuse is a sign that the underlying migraine or headache disorder has not been adequately controlled.
At Pain Spa, the clinical approach should emphasise careful diagnosis, medication-day counting, education, preventive treatment, and selected image-guided interventions where appropriate. Greater occipital nerve blocks and other peripheral nerve blocks may be useful as bridging treatments during withdrawal, particularly when pain distribution suggests trigeminocervical or cranial nerve involvement. Botox and CGRP-targeted therapies have an important role in chronic migraine patients, especially when standard withdrawal and oral preventive strategies are insufficient.
The most effective treatment plan is individualised, realistic, and supportive. Patients should not feel blamed for medication overuse; they should feel that there is a structured way out of the cycle.